Close monitoring of cardiac performance and recognition of risk factors may minimize trastuzumab-induced cardiotoxicity in women with breast cancer.
May support monitoring in trastuzumab-treated breast cancer; leaves open need for randomized confirmation.
Cardiac performance should be closely monitored in women treated with trastuzumab. Recognizing potential risk factors along with careful attention to symptoms/LVEF measurements could minimize the occurrence of TIC in this population.
No takes yet. Share an insight, caveat, or question.
Jawa et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: